La vendita allo scoperto per ACRES Commercial Realty dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ACRES Commercial Realty. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ACRES Commercial Realty (NYSE:ACR) Azioni, Report sulle vendite allo scoperto

ACRES COMMERCIAL REALTY CORP

ACRES Commercial Realty

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

ACRES Commercial Realty Corp. Common Stock

ACRES Commercial Realty Corp

ASIA CARBON INDUSTRIES by Asia Carbon Industries, Inc.

Asia Carbon Industries Inc

Acreage Holdings Inc Ordinary Shares Class D (Sub Voting)

Ares Commercial Real Estate Corporation Common Stock

Ares Commercial Real Estate Corp

Accor SA

AMERICAN CLEAN RESOURCES by American Clean Resources Group Inc.

American Clean Resources Group Inc

Acreage Holdings Inc Ordinary Shares Class E (Sub Voting)

ATACAMA RESOURCES INTL by Atacama Resources International, Inc.

Atacama Resources International Inc

ACROPOLIS INFRASTRUCTURE ACQUISITION CORP CL A

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

Americrew Inc

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics Inc

Acerinox SA

ACRES Commercial Realty Corp. 8.625% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock

ACRES Commercial Realty Corp. 7.875% Series D Cumulative Redeemable Preferred Stock

The Hartford Insurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) short percent of float has fallen 7.53% since its last report. The company recently reported that it has 2.90 million shares sold short, which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>The Hartford Insurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747076426_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for The Hartford Insurance Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing The Hartford Insurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, The Hartford Insurance Gr's peer group average for short interest as a percentage of float is 2.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into The Hartford Insurance Gr's Recent Short Interest

Looking into the current session, ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares are trading at $10.20, after a 9.09% spike. Moreover, over the past month, the stock increased by 26.24%, but in the past year, fell by 21.48%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1747076424_0.png" alt="Past Year Chart" />

<h3>ZoomInfo Technologies P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 26.22 in the Interactive Media &amp; Services industry, ZoomInfo Technologies Inc. has a higher P/E ratio of 116.88. Shareholders might be inclined to think that ZoomInfo Technologies Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747076424_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

Price Over Earnings Overview: ZoomInfo Technologies

In the preceding three months, 7 analysts have released ratings for Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Anglogold Ashanti, revealing an average target of $40.64, a high estimate of $53.00, and a low estimate of $34.00. Witnessing a positive shift, the current average has risen by 13.93% from the previous average price target of $35.67.
<img src="https://www.benzinga.com/files/images/story/2025/1747076423_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Anglogold Ashanti is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.50</td>
<td>$42.00</td>
</tr>
<tr>
<td>Patrick Jones</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Leroy Mnguni</td>
<td>HSBC</td>
<td>Announces</td>
<td>Reduce</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Josh Wolfson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Josh Wolfson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Anglogold Ashanti. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Anglogold Ashanti compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Anglogold Ashanti's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Anglogold Ashanti's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Anglogold Ashanti analyst ratings.</a>
<h2>Get to Know Anglogold Ashanti Better</h2>
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
<h3>Anglogold Ashanti: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Anglogold Ashanti's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 39.33%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Anglogold Ashanti's net margin excels beyond industry benchmarks, reaching 26.86%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Anglogold Ashanti's ROE excels beyond industry benchmarks, reaching 8.74%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.28%, the company showcases effective utilization of assets.
Debt Management: Anglogold Ashanti's debt-to-equity ratio surpasses industry norms, standing at 0.32. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Anglogold Ashanti Stands With Analysts

Dynatrace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) short percent of float has fallen 15.77% since its last report. The company recently reported that it has 5.58 million shares sold short, which is 1.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Dynatrace Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747076422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dynatrace has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dynatrace's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Dynatrace's peer group average for short interest as a percentage of float is 3.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What's Driving the Market Sentiment Around Dynatrace?

In the last three months, 11 analysts have published ratings on Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Intellia Therapeutics, revealing an average target of $35.91, a high estimate of $68.00, and a low estimate of $10.00. A 34.04% drop is evident in the current average compared to the previous average price target of $54.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1747076415_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Intellia Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Andy Chen</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intellia Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Intellia Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Intellia Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Intellia Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NTLA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intellia Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Intellia Therapeutics</h2>
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
<h3>A Deep Dive into Intellia Therapeutics's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Intellia Therapeutics's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -42.54%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Intellia Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -687.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Intellia Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -13.84%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Intellia Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.5%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.15.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTLA

Forecasting The Future: 11 Analyst Projections For Intellia Therapeutics

WIIM

Beamr Imaging shares are trading higher after the company issued a Q1 shareholder letter highlighting the state of growth, sales, strategy, and demand for the business.

<a href="https://www.nytimes.com/2025/05/12/business/fed-economy-stagflation-trump-tariffs.html">https://www.nytimes.com/2025/05/12/business/fed-economy-stagflation-trump-tariffs.html</a>

Macro Economic Events

Econ #s

Economics

Federal Reserve

'Fed Official Still Bracing for Economic Shock Despite China Tariff Pause'- New York Times

SoundHound AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) stock is trading higher Monday after the U.S. and China agreed to a temporary reduction in most tariffs on <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">each other&#8217;s goods</a>.
What To Know: The trade deal will lower U.S. tariffs on Chinese imports from 145% to 30% and Chinese levies on U.S. goods from 125% to 10% for a three-month period, according to <a href="https://www.msn.com/en-us/money/markets/us-china-agree-to-lower-most-tariffs-for-90-days-amid-trade-talks/ar-AA1EAVhw?ocid=BingNewsSerp">The Washington Post</a>.
Bessent said in a news conference that, "The consensus from both delegations this weekend is that neither side wants a decoupling, and what had occurred with these very high tariffs was the equivalent of a trade embargo, and neither side wants that.&#8221; Bessent further added that both sides want more balanced trade.
The current 30% U.S. tariff on Chinese goods includes a 10% base rate and an additional 20% imposed by President Trump in response to concerns about China&#8217;s production of fentanyl-related chemicals.
The U.S. is also reportedly pushing for increased Chinese purchases of American goods.
SoundHound stock may be trading higher as the tariff reduction could boost optimism that improved U.S.-China relations will strengthen global economic conditions.
Related Link: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45356352/soundhound-ai-expansion-in-autos-and-dining-plus-q4-profit-target-fuels-bullish-analyst-view">SoundHound AI Expansion In Autos And Dining, Plus Q4 Profit Target, Fuels Bullish Analyst View</a>
SOUN Price Action: At the time of writing, SoundHound shares are trading 21.6% higher at $10.92, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
Image: via Shutterstock

Movers

SOUN

SoundHound AI Stock Is Rising Monday: What's Going On?

<a href="https://punchbowl.news/wp-content/uploads/SMITMO_017_xml.pdf" title="https://punchbowl.news/wp-content/uploads/SMITMO_017_xml.pdf">https://punchbowl.news/wp-content/uploads/SMITMO_017_xml.pdf</a>

House Republicans Introduce Bill That Would Exempt Qualified Tips From Tax

PAPL

Pineapple Financial shares are trading lower after the company denied false claims regarding a reverse stock split.

INHD

INHD stock has given up its prior gain. INNO HOLDINGS shares were trading higher after the company announced a strategic cooperation with New Life Technology Development on developing a B2B marketplace platform.

An agreement by the U.S. and China to lower tariff amounts could send technology stocks to new highs, according to a well-known sector analyst.
What Happened: The U.S. is lowering its tariff on goods imported from China from 145% to 30%, while China has agreed to lower its tariff on U.S. goods from 125% to 10%. Both moves are temporarily <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">in place for 90 days</a>.
The deal announced Monday morning came after a series of weekend negotiations between the two countries. 
Wedbush analyst Dan Ives discussed the winners in the tech industry in an interview <a href="https://www.bloomberg.com/news/videos/2025-05-12/us-china-tariff-pause-is-dream-scenario-for-tech-ives-video?sref=TBDibEcD">with</a> Bloomberg.
The Big Winners: Ives highlighted Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) as one of the biggest winners in the technology sector on the heels of the tariff news.
"It puts new tech highs back on the table now for 2025," Ives said.
Ives said tariffs have been the front and center story for Apple with the company hedging and saying it would shift production to India. With the news, Ives said this could slow down the shift to India for the iPhone 17 with China getting the vast majority of the production volume.
"There was a window here where this needed to change."
Ives said the 30% tariff could go lower in the future to a 15% to 20% range, something that might start to get baked into stock prices.
"It's a game changer."
Also Read: <a href="https://www.benzinga.com/25/05/45350995/nrg-energy-posts-upbeat-earnings-joins-tesla-apple-amazon-and-other-big-stocks-moving-higher-on-monday">NRG Energy Posts Upbeat Earnings, Joins Tesla, Apple, Amazon And Other Big Stocks Moving Higher On Monday</a>
Ives said Apple has "pricing power to an extent" and the tariff news still gives the company the flexibility to raise prices if it wants.
The analyst said Apple's AI strategy really needs to produce the iPhone 17 because a large portion of the company's installed base looking to upgrade phones in the next two to three years.
"This puts that key bull case back on the table."
The other big winner named by Ives from the China tariff news is Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
"Tesla's going to be a huge beneficiary in terms of what we see in this de-escalation of the U.S., China tariffs," Ives told CNBC.
During his interview with Bloomberg, Ives was asked about Tesla CEO Elon Musk's whereabouts after his time spent in the White House was viewed as a distraction to many.
"Thankfully not in the White House," Ives said of Musk's whereabouts.
Ives said Musk is back at Tesla driving the company's autonomy strategy ahead of a robotaxi launch in June.
"It speaks to why Tesla is up. You need your leader back. They got their biggest asset back."
Ives said investors will look back and view this as a "pivotal moment for the Tesla story."
Other Winners: During a CNBC interview, Ives said the trade progress between China and the U.S. is a positive for many stocks in the technology sector.
"If you are a tech investor, this is a dream scenario," Ives said.
Ives said the tariff change could see NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) as a big winner.
"They are going to be one especially given the China tariffs."
Ives also named Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) as companies that the tariff news could be bullish for.
A slide shared during Ives&#8217; discussion about Tesla being a big winner also showed cybersecurity stock picks from Wedbush. That slide included Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), CrowdStrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), Zscaler Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>), CyberArk Software Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) and Check Point Software Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>). Read Next: <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation"> • Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation</a>
Photo: Mer_Studio/Shutterstock

Tech

AAPL

CHKP

CRWD

CYBR

MSFT

NVDA

ORCL

PANW

PLTR

TSLA

China Tariff De-Escalation Biggest Winners Include Tesla, Apple: 'New Tech Highs Back On The Table Now For 2025'

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading higher Monday after the U.S. and China agreed to a temporary reduction in most tariffs on <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">each other&#8217;s goods</a>.
What To Know: The trade deal will lower U.S. tariffs on Chinese imports from 145% to 30% and Chinese levies on U.S. goods from 125% to 10% for a three-month period, according to <a href="https://www.npr.org/2025/05/12/nx-s1-5395027/us-china-tariffs-deal-trade-war-beijing-washington">NPR</a>.
Vice Premier He Lifeng led the discussions for China, while Trade Representative Jamieson Greer and Treasury Secretary Scott Bessent represented the U.S. side.
At a press conference, Bessent said the two sides recognized mutual interests, including a shared goal of balanced trade. Greer added that the countries see a "positive path forward" in cooperating to fight fentanyl smuggling.
The current U.S. tariff structure includes a 10% base tariff on all imports, plus an extra 20% implemented earlier this year by President Donald Trump amid concerns over Chinese production of fentanyl-related chemicals.
The U.S. is also reportedly negotiating with China to boost its purchases of American goods.
Tesla stock may be trading higher as a reduction in tariffs could alleviate supply chain uncertainty in the sector. Other auto stocks, including Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), are also trading higher following the news.
Related Link: <a href="https://www.benzinga.com/insights/earnings/25/05/45355288/a-look-ahead-acurx-pharmaceuticalss-earnings-forecast">A Look Ahead: Acurx Pharmaceuticals&#8217;s Earnings Forecast</a>
TSLA Price Action: At the time of publication, Tesla stock is trading 6.3% higher at $317.00, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
Image: via Shutterstock

LCID

Tesla Stock Is Climbing Monday: What's Going On?

A&nbsp;<a href="https://www.tker.co/p/sales-pull-forward-frontrunning-tariffs">big economic question right now</a>: To what degree does today's economic activity reflect a pull forward of purchases that would've occurred further down the road?
<a href="https://www.tker.co/p/companies-react-to-tariffs">One of the actions</a>&nbsp;some companies have taken to&nbsp;<a href="https://www.tker.co/p/wall-street-brief-explanation-tariffs">mitigate the impact of future tariffs</a>&nbsp;has been to pulling forward expected future purchases and stockpiling goods before costs go up.
Various&nbsp;<a href="https://www.tker.co/p/sales-pull-forward-frontrunning-tariffs">anecdotes from companies</a>&nbsp;and a&nbsp;<a href="https://www.tker.co/p/us-gdp-q1-2025-imports-final-sales">spike in imports</a>&nbsp;at the beginning of this year suggest this pull-forward&nbsp;<a href="https://www.tker.co/p/sales-pull-forward-frontrunning-tariffs">could be significant</a>. Here are some notable quotes from Q1 earnings season:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"Our clients are getting ready. We&#8217;re seeing some accelerating of imports to stockpile inventories." &#8211;&nbsp;<a href="https://finance.yahoo.com/news/q1-2025-citigroup-inc-earnings-090042297.html">Citigroup</a>
"Looking outside the U.S., demand for U.S. inbound services surged as customers pull forward inventory purchases ahead of expected tariff changes." &#8211;&nbsp;<a href="https://finance.yahoo.com/news/q1-2025-united-parcel-inc-042120974.html">UPS</a>
"For transparency, you will see that we did build ahead inventory, and that&#8217;s reflected in our manufacturing purchase obligations that you&#8217;ll see on the quarterly filing when it comes out." &#8211;&nbsp;<a href="https://finance.yahoo.com/news/q2-2025-apple-inc-earnings-131259628.html">Apple</a>
"We&#8217;ve done some forward buys of inventory where we&#8217;re the first-party seller. Our third-party sellers have pulled forward a number of items, so they have inventory here as well." &#8211;&nbsp;<a href="http://looking%20outside%20the%20us,%20demand%20for%20us%20inbound%20services%20surged%20as%20customers%20pull%20forward%20inventory%20purchases%20ahead%20of%20expected%20tariff%20changes/">Amazon</a>
"We built some inventory where possible in certain items as we anticipate that to happen. So that gives a little relief of amounts needed to in some of the items. But the impact should be mostly concentrated in the second half." &#8211;&nbsp;<a href="https://finance.yahoo.com/news/q1-2025-kraft-heinz-co-055550241.html">Kraft Heinz</a>
"As a precaution, we&#8217;ve taken steps to build inventory in certain markets to mitigate potential tariff impact in the short term." &#8211;&nbsp;<a href="https://uk.finance.yahoo.com/news/q2-2025-wd-40-co-021703140.html">WD-40</a>
</blockquote>
So how much extra stuff did companies stockpile?
Different analysts will give you different answers.
<h2 class="wp-block-heading">‘About 1 to 2 months' &#x23f3;</h2>
Deutsche Bank's Binky Chadha analyzed the data to estimate how much extra inventory companies have accumulated.
It's not much.
"In clear evidence of pre-buying, goods imports surged in Q1, especially in March, but relative to the prior run rate of $275bn a month, we estimate the excess imports over the last 3 months were about $190bn, or around 3 weeks extra," Chadha wrote in his May 2 research note.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7bba64bd-632e-4bde-b3bf-d84a9f218172_2058x1446.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7bba64bd-632e-4bde-b3bf-d84a9f218172_2058x1446.png" alt="" /></a><figcaption class="wp-element-caption">"Pre-buying or excess imports has created a buffer of about 3 weeks," Chadha wrote. (Source: Deutsche Bank)</figcaption></figure>
The way companies manage inventory has changed&nbsp;<a href="https://www.tker.co/p/supply-chain-crisis-over">in recent years</a>.
"Companies typically maintain about 3 months of inventory," Chadha wrote. "They have been raising that buffer over the last 10 years, especially since the COVID pandemic supply chain disruptions, and the lowest levels in the last 10 years have been about 2 months, which suggests companies could run their buffers down for a month at most in hopes for a tariff reprieve."
In other words, companies were already carrying extra inventory before President Trump&nbsp;<a href="https://www.tker.co/p/boycott-america-gdp-stock-market-negative-impact">unveiled his aggressive view on tariffs</a>.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1a2aeec6-924c-4be7-bc0c-8f353c22e239_2050x1536.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1a2aeec6-924c-4be7-bc0c-8f353c22e239_2050x1536.png" alt="" /></a><figcaption class="wp-element-caption">"Excess imports combined with inventory rundowns gives companies about 1 to 2 months before the tariff impacts start to bite," Chadha said. (Source: Deutsche Bank)</figcaption></figure>
So while Chadha's estimate of "about 1 to 2 months" of buffer for S&amp;P 500 companies is arguably significant, it doesn't even buy a quarter's worth of time.
<h2 class="wp-block-heading">Some analysts think it's less &#x231b;&#xFE0F;</h2>
In a separate analysis of retailer inventories,&nbsp;<a href="https://institute.bankofamerica.com/content/dam/economic-insights/retail-inventories.pdf">BofA analysts</a>&nbsp;expressed skepticism toward the idea that warehouses are well stocked. From their note (emphasis added):
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"There was a surge in imports of consumer goods into the U.S. in March, according to Census Bureau data. Does this mean retailers&#8217; inventories are set to swell? In our view, no.&nbsp;The ratio of retailers&#8217; inventories to their monthly sales was not especially high in recent data to begin with. And at the same time, consumers also appear to have been buying ahead, with Bank of America internal data showing strength in consumer durables spending in March and April. Moreover, Bank of America internal data on retailers&#8217; payments to transportation and shipping companies does not suggest a big ramp up in inventories. And it appears container shipments into Los Angeles are likely down in May. So we think it is possible retail inventories may actually look &#8216;lean&#8217; in coming months."
</blockquote>
It's worth noting that the most recent retail inventories data from the Census only goes through February. So those particular figures are a bit stale.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7abe6a9a-99fd-48c8-b7e3-6ff415655e10_1566x780.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7abe6a9a-99fd-48c8-b7e3-6ff415655e10_1566x780.png" alt="" /></a><figcaption class="wp-element-caption">As of February, retailer inventories hadn't changed much from the recent months' trend. (Source:&nbsp;<a href="https://institute.bankofamerica.com/content/dam/economic-insights/retail-inventories.pdf">BofA</a>)</figcaption></figure>
That said, BofA makes a good point about consumers "buying ahead." This suggests that a lot of goods left warehouses as quickly as they came in. This is consistent with&nbsp;<a href="https://www.tker.co/p/hard-data-soft-data-tariff-disconnect">government data on consumer spending</a>, which has been very strong.
Goldman Sachs' David Kostin analyzed the S&amp;P 500 and came to a similar conclusion.
"1Q data do not show a buildup of inventories," Kostin wrote on Friday. "The S&amp;P 500 inventory to sales ratio declined year/year, with the largest declines in the Autos and Consumer Durables &amp; Apparel industries. However, many retailers have yet to report 1Q results."
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3c84db36-1bad-4ecd-ab78-680753bb043c_2500x1126.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3c84db36-1bad-4ecd-ab78-680753bb043c_2500x1126.png" alt="" /></a><figcaption class="wp-element-caption">The inventory/sales ratio is actually trending lower. (Source Goldman Sachs)</figcaption></figure>
The&nbsp;<a href="https://www.tker.co/i/161227758/review-of-the-macro-crosscurrents">March retail sales report</a>&nbsp;showed an unusual spike in autos sales, which supports the idea that consumers pulled forward purchases to front-run tariffs.
To Kostin's point about fresh data, retailers will be announcing their Q1 results in the coming weeks. On Thursday morning we get&nbsp;<a href="https://corporate.walmart.com/news/2025/05/08/walmart-to-host-first-quarter-earnings-conference-call-may-15-2025">Walmart's earnings</a>. That day also comes with the April retail sales and March inventories reports. Everyone will be watching for clues about inventory builds as well as how much inventory was cleared out by sales pulled forward.
<h2 class="wp-block-heading">Zooming out &#x1f52d;</h2>
Even if we had a more clear understanding of inventory levels, the bigger issue continues to be the uncertainty around tariffs.
If we ultimately get very high tariffs, then inventory stockpiling would've been a good move. If any new tariffs are low, then inventory stockpiling could prove to be a costly error.
There's also the possibility that proposed tariffs or any tariff deals continue to get delayed, and this&nbsp;<a href="https://www.tker.co/p/economic-data-earnings-results-ambiguous">uncertainty nightmare</a>&nbsp;persists.
<h2 class="wp-block-heading">The big picture &#x1f5bc;&#xFE0F;</h2>
These are&nbsp;<a href="https://www.tker.co/p/market-pundits-with-all-answers-dont-know">uncertain times</a>.
The economic data is&nbsp;<a href="https://www.tker.co/p/hard-data-soft-data-tariff-disconnect">sending ambiguous signals</a>. Managers are having an unusually hard time&nbsp;<a href="https://www.tker.co/p/companies-not-withdrawing-guidance-exclude-tariff-impact">forecasting the near future</a>&nbsp;for the businesses. And investors and analysts are having an unusually hard time&nbsp;<a href="https://www.tker.co/p/price-sensitive-to-earnings-multiple-assumptions">modeling where stock prices</a>&nbsp;are headed in the coming months and quarters.
It's periods like this where long-term investors&nbsp;<a href="https://www.tker.co/p/stock-market-time-invested-positive-returns">have an edge</a>:&nbsp;<a href="https://www.tker.co/p/best-investment-advice-time">Time</a>.
"Nobody knows what the market is going to do tomorrow, next week, next month," Warren Buffett&nbsp;<a href="https://www.tker.co/p/warren-buffett-berkshire-hathaway-2025-meeting">said last week</a>. But as he&nbsp;<a href="https://www.tker.co/p/warren-buffett-berkshire-meeting-market-timing">often does</a>, he argued, "The long-term trend is up."
There's basically three scenarios investors always have to consider: 1) Things improve from here, and the market goes up; 2) Things get worse before they get better, which means markets could fall before resuming a more firm rally; or 3) Things get worse and never get better.
If we're facing scenario 3, then we may have bigger problems than stocks not recovering. But scenario 3 has&nbsp;<a href="https://www.tker.co/i/42137695/the-long-game-is-undefeated">never played out</a>.
Scenarios 1 and 2 favor long-term investors. Maybe things get worse before they get better. (Note:&nbsp;<a href="https://www.tker.co/p/bofa-on-timing-market-peaks-stay-invested">Timing market</a>&nbsp;bottoms is&nbsp;<a href="https://www.tker.co/p/quotes-im-thinking-about-as-stocks-fall">nearly impossible</a>.) But staying long the stock market covers you in case the low of this cycle is behind us.
<a href="https://www.tker.co/p/pull-forward-imports-months-inventory-stockpiled/comments"></a><a></a>
<a href="javascript:void(0)"></a>

Equities

Long Ideas

Broad U.S. Equity ETFs

Opinion

ETFs

How Much Inventory Did Companies Actually Build Ahead Of Tariffs?

Shopify Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) shares jumped 14.8% to $105.26 Monday afternoon. It was earlier <a href="https://ir.nasdaq.com/news-releases/news-release-details/shopify-inc-join-nasdaq-100-indexr-beginning-may-19-2025#:~:text=(Nasdaq%3A%20SHOP)%2C%20will,100%20Equal%20Weighted%E2%84%A2%20Index.">announced</a> the stock will join the Nasdaq-100 beginning May 19, replacing MongoDB. The move positions Shopify among the market's top tech names and could attract index-fund inflows.
What Else: The e-commerce platform <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45328107/shopify-shows-strong-global-momentum-but-guidance-raises-questions-on-profitability-path">reported</a> strong first-quarter results last Thursday, with revenue climbing 26.8% year-over-year to $2.36 billion, beating estimates. 
Gross merchandise volume <a href="https://www.benzinga.com/pressreleases/25/05/g45332641/shopify-inc-to-join-the-nasdaq-100-index-beginning-may-19-2025">rose 22.8%</a> to $74.75 billion, though adjusted EPS of 25 cents narrowly missed forecasts. Analysts cited robust growth in global merchant activity and resilient consumer demand as key drivers.
Sentiment also improved as the U.S. and China reached a <a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation">landmark agreement</a> to slash tariffs, easing recession and inflation fears. With U.S. tariffs dropping from 145% to 30% and China's from 125% to 10%, global trade pressures are receding. 
Shopify noted minimal exposure to Chinese imports, suggesting limited direct impact from prior tariff risks. Analysts from Goldman Sachs and Piper Sandler expect continued growth into the second-quarter, with revenue forecast around $2.56 billion and EPS of 30 cents. Shopify's international momentum meanwhile remains a key pillar of its bullish outlook.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45353863/new-inflation-data-hits-tuesday-why-it-could-kill-fed-rate-cut-hopes">New Inflation Data Hits Tuesday: Why It Could Kill Fed Rate Cut Hopes</a>
<h2 class="wp-block-heading">How To Buy SHOP Stock</h2>
By now you're likely curious about how to participate in the market for Shopify &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Shopify, which is trading at $104.42 as of publishing time, $100 would buy you 0.96 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SHOP has a 52-week high of $106.35 and a 52-week low of $69.84.

SHOP

Why Shopify (SHOP) Stock Hit A New 52-Week High Today

Citigroup analyst Ygal Arounian maintains Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Neutral and lowers the price target from $4 to $3.9.

Price Target

Citigroup Maintains Neutral on Outbrain, Lowers Price Target to $3.9

Citigroup analyst Andrew Kaplowitz maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $127 to $133.

Citigroup Maintains Buy on Emerson Electric, Raises Price Target to $133

BofA Securities analyst Brad Sills maintained a Buy rating on Salesforce, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/CRM/analyst-ratings" rel="noreferrer noopener">price target of $350</a> on Monday.
Salesforce Sales Cloud is the company&#8217;s flagship offering, generating estimated subscription revenue of $7.9 billion in fiscal 2026. It is growing at an estimated 9% growth rate (constant currency), keeping pace with Sills&#8217; estimate for total company subscription revenue.
Over the years, Salesforce has expanded its offering from front office applications (both organically and inorganically) into other horizontal and vertical industry applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44908035/salesforces-investment-in-ai-and-data-cloud-boosts-long-term-growth-outlook-analyst-confident" rel="noreferrer noopener">Salesforce&#8217;s Agentforce AI, Data Cloud Strengthen Long-Term Growth Potential: Analyst</a>
Sales Cloud represents 21% of Sills&#8217; fiscal 2026 total subscription revenue and remains a core growth business.
Sills estimated that 40% of 135,000 Salesforce customers (not on freemium) are currently on Sales Cloud, which represents 4.9 million subscribers, a 10% penetration of the global addressable market (16.2 million sales-related workers per US Bureau of Labor Statistics and international = 2 x US).
Sales Cloud is priced per user per month based on the edition chosen, with each edition adding more advanced features. The per-user pricing allows each user to manage their login.
The Starter Suite ($25/user/month) includes only the basic feature for managing accounts and leads. In contrast, Einstein 1 Sales ($500/user/month) consists of all features, including Data Cloud and the Agentforce agentic AI offering.
Sales Cloud is one of Salesforce&#8217;s core growth businesses (along with Service Cloud), keeping pace with an estimated total subscription growth of 9%-10% and showing no slowdown.
Sales Cloud expansion deals are driven by Industry Cloud upsells, Revenue Cloud upsells, and the pull-through of more seats to support Revenue Cloud, Industry Cloud, and Data Cloud deployments.
Revenue Cloud is Salesforce&#8217;s CPQ solution. Channel feedback suggests Revenue Cloud and the migration from CPQ to Revenue Cloud Advanced (RCA) is driving additional growth for Sales Cloud.
Revenue Cloud is priced as an add-on to Sales Cloud for a $200 monthly subscription versus $165 for Sales Cloud Enterprise, representing an average 120% subscription uplift.
Sales Cloud is the core system of record for the entire Salesforce CRM stack.
Gartner forecasts Sales Cloud to sustain a 25% share of the $39 billion Sales CRM industry through 2027.
However, Salesforce is forecast to capture the most incremental industry growth, driven by advantages such as its integrated platform with internal sales systems, business intelligence features for projection analysis, and AI innovation.
Sills&#8217; calls with SI partners suggested that upselling premium-priced Industry Cloud (estimated 15% ASP uplift to enterprise customers) and Revenue Cloud (12% ASP uplift) represent key growth drivers for Sales Cloud.
Agentforce projects are also mentioned to widen the Sales Cloud user base in many enterprises, driven by demand for a more complete data set and user base.
Finally, while the softening macro pushes out Sills&#8217; near-term expectation for Agentforce revenue, the analyst noted that this would represent a material source of incremental Sales Cloud growth in the coming years.
In his base case Sales Cloud model, the analyst modeled a 5-year CAGR of 10%, assuming 7.5 million subscribers, or 13% user penetration of global sales TAM (up from 10% in fiscal 2026), ASP of $143 (from $135 in fiscal 2026) and 8% Agentforce revenue contribution to Sales Cloud growth.
In a reasonable upside case, the analyst arrived at a 5-year CAGR of 12%, assuming similar user penetration, ASP of $157 from higher Revenue Cloud and Industry Cloud penetration, and a 13% Agentforce contribution to growth.
Sills projected fiscal 2026 revenue of $40.31 billion.
Price Action: CRM shares are trading higher by 4.62% to $288.17 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45324239/apples-upcoming-chips-aim-to-challenge-meta-in-the-smart-glasses-battle-report" target="_blank" rel="noreferrer noopener">Apple&#8217;s Upcoming Chip Aims To Challenge Meta In Smart Glasses Battle: Report</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Reiteration

Salesforce Sales Cloud, AI Integration, And Cloud Upsells Drive Analyst Confidence In Long-Term Growth

Citigroup analyst Kyle Menges maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Buy and raises the price target from $320 to $350.

Citigroup Maintains Buy on Cummins, Raises Price Target to $350

<a href="https://www.benzinga.com/topic/s-p-500">The S&amp;P 500</a> is quietly pulling off a winning streak that even some bulls didn't see coming. For the second quarter in a row, the index has notched double-digit earnings growth &#8211; clocking in at 13.4% for the first quarter &#8211; leaving ETF investors in the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) with something to cheer about.
According <a href="https://insight.factset.com/sp-500-earnings-season-update-may-9-2025?utm_source=Direct&amp;utm_medium=Email&amp;utm_campaign=FO-05-09-2025&amp;utm_content=httpsinsightfactsetcomsp500earningsseasonupdatemay92025">to</a> FactSet, 90% of S&amp;P 500 companies have reported results so far, and 78% of them beat earnings estimates &#8211; not only topping the 10-year average (75%) but also surpassing the five-year norm (77%). While the average earnings surprise of 8.5% came in just below the 5-year average (8.8%), it&#8217;s well ahead of the 10-year benchmark (6.9%).
Read Also: <a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says">Wall Street Rallies After US Seals First Trade Deal: &#8216;You Better Go Out And Buy Stock,&#8217; Trump Says</a>
<h2 class="wp-block-heading">3 Sectors That Fueled Surprise Profits</h2>
This uptick didn't happen overnight. Since the end of the first quarter, earnings growth estimates have steadily climbed &#8211; from 7.1% on March 31 to 12.8% last week, now landing at a strong 13.4%. Much of the fuel came from surprise profits in Communication Services, Financials, and Health Care.
Eight out of eleven sectors are showing year-over-year earnings growth, with Health Care, Communications Services, Info Tech and Utilities leading the pack. Even more impressively, this is now the seventh straight quarter of earnings growth for the S&amp;P 500.
<h2 class="wp-block-heading">62% S&amp;P 500 Companies Delivered Revenue Beats</h2>
The revenue side of the story is more muted &#8211; 62% of companies beat top-line expectations (below the 5-year average of 69%), with aggregate revenue surprises averaging just 0.7%. But that still translates to a 4.8% revenue growth rate &#8211; the 18th consecutive quarter of sales growth.
Looking ahead, analysts are expecting earnings growth to cool slightly, with forecasts of 5.2%, 7.4%, and 6.7% for the second through fourth quarter. But with a forward P/E of 20.5 (above the 5- and 10-year averages), markets are already pricing in strength &#8211; or at least resilience.
For ETF investors watching SPY, IVV, or VOO, the S&amp;P 500 just sent a second bullish signal in a row: earnings are holding up &#8211; and then some.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45283497/federal-reserve-will-be-the-last-to-cut-says-expert-anticipating-4-cuts-in-2025-a-thaw-in-us-china-trade-dispute-is-good-news">Federal Reserve &#8216;Will Be The Last To Cut&#8217; Rates, Says Expert Who Still Expects Four Cuts In 2025</a></li>
</ul>
Photo: Shutterstock

Earnings

Earnings Beats

S&P 500 Q1 Earnings Jump 13.4% - SPY Investors Just Got Their Second Straight Double-Digit Surprise

Press Releases

Real Estate

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2024

Dividends

ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock

ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program

ACRES Commercial Realty Corp. to Report Results for Fourth Quarter 2024

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FOURTH QUARTER 2024 AND YEAR ENDED DECEMBER 31, 2024

ACRES Commercial Realty Corp. Announces Redemption of CRE Securitizations and Closing of a $940 Million Managed Facility Backed by Commercial Mortgage Loans

Comments

ACRES Commercial Realty

Vendite allo scoperto

ACRES Commercial Realty (NYSE:ACR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO